retatrutide weight loss study results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A in those with concurrent obesity and type 2 diabetes. 📊 Mean body change at 80 weeks: ⬇️ Retatrutide just delivered the first

This is not a criticism but rather an inevitable aspect of addressing such complex subjects

Depression patients also present increased TNF, macrophage colony-stimulating factor (MCSF), and IL-12 in the intestinal mucosa and reduced abundances of Clostridium, Roseburia, Haemophilus, SMB53 , and Turicibacter , which are positively correlated with propionate and butyrate levels [336]

The concentration of the resulting solution is determined by the diluent volume added

doi:10.1021/bi00171a002

Truth: While weight loss is a common benefit, GLP-1 medications are primarily designed to regulate blood sugar and improve metabolic health

This article explores how GLP-1 works in the body to drive these outcomes, the differences between natural GLP-1 and synthetic agonists, and how to effectively navigate treatment options for sustainable health